AVI Gets Patent For Ebola Drug

AVI Biopharma (NASDAQ: AVII), the Portland, OR-based developer of RNA interference drugs, said today it has gotten the second of two patents needed for its drug that treats infections with Ebola Zaire virus. The patents cover composition of matter and methods for treating Ebola with a range of compounds, and they expire Oct. 31, 2025, AVI said.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: